{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:26:34Z","timestamp":1794590794672,"version":"4.9.1"},"reference-count":60,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Only a handful of anticoagulants have reached the clinic to treat and prevent thrombotic episodes in the millions of patients with cardiovascular, cancer, viral (COVID-19), and metabolic diseases. In this study, we report the discovery, chemical synthesis, mechanistic biochemistry, pharmacology, and toxicology of SB-01, a novel, allosteric, activated human factor XIa (hFXIa) inhibitor that displays potent antithrombotic activity in preclinical models. SB-01 is a synthetic, highly sulfated, aromatic agent that binds in both anion-binding exosites of hFXIa to induce inhibition of FIX activation. SB-01 inhibited rodent arterial and venous thrombosis at doses of 6 and 3 mg\/kg, respectively. In addition, a twice-a-day regimen of 6 mg\/kg SB-01 was significantly more effective (P&amp;lt; .001) in preventing deep vein thrombosis in animals with lung cancer. Michaelis-Menten kinetics and competition with unfractionated heparin and polyphosphate revealed SB-01 to be an allosteric inhibitor. Critically, at the effective dose of 6 mg\/kg, SB-01 did not significantly increase mouse tail bleeding time or blood loss. Furthermore, SB-01\u2019s anticoagulation could be readily reversed with protamine sulfate, the US Food and Drug Administration\u2013approved antidote for heparin. Finally, SB-01 showed no major adverse effects across multiple toxicological assays including gross, cardiac, metabolic, hematological, and clinical chemistry. Overall, this study presents a structurally and functionally unique, allosteric small molecule as a highly promising candidate for safer anticoagulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019983","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:53:43Z","timestamp":1789768423000},"page":"7621-7633","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["A synthetic, small-molecule, allosteric inhibitor of human factor XIa for thrombosis"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5515-2197","authenticated-orcid":false,"given":"Chiranjeev","family":"Sharma","sequence":"first","affiliation":[{"name":"1Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA"},{"name":"2Center for Drug Discovery, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2096-366X","authenticated-orcid":false,"given":"Rama","family":"Gunta","sequence":"additional","affiliation":[{"name":"1Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA"},{"name":"2Center for Drug Discovery, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar R.","family":"Iyer","sequence":"additional","affiliation":[{"name":"3Spincotech Private Limited, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1608-1250","authenticated-orcid":false,"given":"Rawan M.","family":"Fayyad","sequence":"additional","affiliation":[{"name":"1Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA"},{"name":"2Center for Drug Discovery, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6650-5103","authenticated-orcid":false,"given":"Elsamani I.","family":"Abdelfadiel","sequence":"additional","affiliation":[{"name":"1Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA"},{"name":"2Center for Drug Discovery, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hadsdy","sequence":"additional","affiliation":[{"name":"1Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA"},{"name":"2Center for Drug Discovery, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika J.","family":"Martin","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-9844","authenticated-orcid":false,"given":"Priyanka","family":"Mishra","sequence":"additional","affiliation":[{"name":"5Richmond Veteran Affairs Medical Center, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6257-1456","authenticated-orcid":false,"given":"Bharath Kumar","family":"Villuri","sequence":"additional","affiliation":[{"name":"1Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA"},{"name":"2Center for Drug Discovery, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2937-3268","authenticated-orcid":false,"given":"Nilesh","family":"Pandey","sequence":"additional","affiliation":[{"name":"6Department of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center, Shreveport, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5675-1127","authenticated-orcid":false,"given":"Daniel K.","family":"Afosah","sequence":"additional","affiliation":[{"name":"1Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA"},{"name":"2Center for Drug Discovery, Virginia Commonwealth University, Richmond, VA"},{"name":"7Department of Chemistry, University of North Texas, Denton, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2870-9164","authenticated-orcid":false,"given":"Nehru","family":"Viji Sankaranarayanan","sequence":"additional","affiliation":[{"name":"1Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA"},{"name":"2Center for Drug Discovery, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6618-4004","authenticated-orcid":false,"given":"Bhaumik B.","family":"Patel","sequence":"additional","affiliation":[{"name":"5Richmond Veteran Affairs Medical Center, Richmond, VA"},{"name":"8Virginia Commonwealth University Massey Comprehensive Cancer Center, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1387-3009","authenticated-orcid":false,"given":"Masahiro","family":"Sakagami","sequence":"additional","affiliation":[{"name":"9Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9268-4363","authenticated-orcid":false,"given":"Nirav","family":"Dhanesha","sequence":"additional","affiliation":[{"name":"6Department of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center, Shreveport, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1976-6597","authenticated-orcid":false,"given":"Umesh R.","family":"Desai","sequence":"additional","affiliation":[{"name":"1Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA"},{"name":"2Center for Drug Discovery, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2026111311220909900_bib1","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(20)30211-8","article-title":"Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis","volume":"7","author":"Klemen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026111311220909900_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/bloodadvances.2021005590","article-title":"The incidence of cancer-associated thrombosis is increasing over time","volume":"6","author":"Mahajan","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2026111311220909900_bib3","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis","volume":"174","author":"Khan","year":"2021","journal-title":"Ann Intern Med"},{"issue":"5","key":"2026111311220909900_bib4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/14656566.2025.2475192","article-title":"Factor XI\/XIa inhibitors: a potential solution to anticoagulation dilemmas","volume":"26","author":"Gibson","year":"2025","journal-title":"Expert Opin Pharmacother"},{"issue":"24","key":"2026111311220909900_bib5","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1161\/CIR.0000000000000769","article-title":"Call to action to prevent venous thromboembolism in hospitalized patients: a policy statement from the American Heart Association","volume":"141","author":"Henke","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"2026111311220909900_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0033-1351130","article-title":"Venous thromboembolism prophylaxis","volume":"26","author":"Laryea","year":"2013","journal-title":"Clin Colon Rectal Surg"},{"issue":"8","key":"2026111311220909900_bib7","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3390\/jcm9082467","article-title":"Prevention of venous thromboembolism in 2020 and beyond","volume":"9","author":"Nicholson","year":"2020","journal-title":"J Clin Med"},{"issue":"23","key":"2026111311220909900_bib8","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2026111311220909900_bib9","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/jth.13369","article-title":"C-reactive protein, obesity, and the risk of arterial and venous thrombosis","volume":"14","author":"Horvei","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026111311220909900_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2026111311220909900_bib11","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026111311220909900_bib12","doi-asserted-by":"crossref","first-page":"e1001275","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Horsted","year":"2012","journal-title":"Plos Med"},{"key":"2026111311220909900_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/bjc.2016.143","article-title":"Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data","volume":"115","author":"Walker","year":"2016","journal-title":"Br J Cancer"},{"issue":"9","key":"2026111311220909900_bib14","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2026111311220909900_bib15","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/ATVBAHA.116.306925","article-title":"Factor XI as a therapeutic target","volume":"36","author":"Gailani","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"2026111311220909900_bib16","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N Engl J Med"},{"issue":"11","key":"2026111311220909900_bib17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/ajh.24168","article-title":"Prospective study of circulating factor XI and incident venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE)","volume":"90","author":"Folsom","year":"2015","journal-title":"Am J Hematol"},{"issue":"14","key":"2026111311220909900_bib18","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2009-05-219915","article-title":"Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology","volume":"114","author":"Cushman","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2026111311220909900_bib19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice","volume":"3","author":"Wang","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"19","key":"2026111311220909900_bib20","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","article-title":"A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo","volume":"116","author":"Cheng","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2026111311220909900_bib21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood-2003-01-0324","article-title":"Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates","volume":"102","author":"Gruber","year":"2003","journal-title":"Blood"},{"key":"2026111311220909900_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1172\/JCI781","article-title":"Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor","volume":"101","author":"Minnema","year":"1998","journal-title":"J Clin Invest"},{"issue":"1","key":"2026111311220909900_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"2026111311220909900_bib24","unstructured":"A study to assess the reversal of the anticoagulant effects of milvexian by 4-factor prothrombin complex concentrate (4F-PCC) (part 1) and recombinant human factor VIIa (rFVIIa) (part 2) in healthy participants. ClinicalTrials.gov identifier: NCT04543383. Updated 15 August 2025. Accessed 25 September 2026. https:\/\/clinicaltrials.gov\/study\/NCT04543383?intr=milvexian&rank=8."},{"issue":"8","key":"2026111311220909900_bib25","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1021\/acs.jmedchem.2c02130","article-title":"Factor XIa inhibitors in anticoagulation therapy: recent advances and perspectives","volume":"66","author":"Xie","year":"2023 27","journal-title":"J Med Chem"},{"issue":"17","key":"2026111311220909900_bib26","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1021\/acs.jmedchem.8b00173","article-title":"Factor XIa inhibitors as new anticoagulants","volume":"61","author":"Quan","year":"2018","journal-title":"J Med Chem"},{"issue":"6","key":"2026111311220909900_bib27","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/med.21503","article-title":"Recent advances in the discovery and development of factor XI\/XIa inhibitors","volume":"38","author":"Al-Horani","year":"2018","journal-title":"Med Res Rev"},{"issue":"7","key":"2026111311220909900_bib28","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1021\/acs.jmedchem.3c00132","article-title":"Designing smaller, synthetic, functional mimetics of sulfated glycosaminoglycans as allosteric modulators of coagulation factors","volume":"66","author":"Abdelfadiel","year":"2023","journal-title":"J Med Chem"},{"issue":"1","key":"2026111311220909900_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1021\/cb3005935","article-title":"Diversity of allosteric regulation in proteases","volume":"8","author":"Merdanovic","year":"2013","journal-title":"ACS Chem Biol"},{"issue":"18","key":"2026111311220909900_bib30","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1002\/cbic.200800528","article-title":"Allosteric regulation of proteases","volume":"9","author":"Hauske","year":"2008","journal-title":"Chembiochem"},{"issue":"12","key":"2026111311220909900_bib31","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1111\/jth.14606","article-title":"A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding","volume":"17","author":"Al-Horani","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2026111311220909900_bib32","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/jth.13254","article-title":"Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ib\u03b1-binding and heparin-binding site of thrombin","volume":"14","author":"Mehta","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026111311220909900_bib33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1399-6576.2005.00602.x","article-title":"Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII","volume":"49","author":"Nielsen","year":"2005","journal-title":"Acta Anaesthesiol Scand"},{"issue":"9","key":"2026111311220909900_bib34","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/bloodadvances.2023012282","article-title":"Interactions between integrin \u03b19\u03b21 and VCAM-1 promote neutrophil hyperactivation and mediate poststroke DVT","volume":"8","author":"Pandey","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"2026111311220909900_bib35","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1016\/j.jtha.2024.08.023","article-title":"Enhanced venous thrombosis and hypercoagulability in murine and human metabolic dysfunction-associated steatohepatitis","volume":"22","author":"Pandey","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2026111311220909900_bib36","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood.2024025322","article-title":"Structure and interactions of the proteins from the contact system","volume":"146","author":"Emsley","year":"2025","journal-title":"Blood"},{"issue":"15","key":"2026111311220909900_bib37","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"issue":"15","key":"2026111311220909900_bib38","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.2023020719","article-title":"Biology of factor XI","volume":"143","author":"Moellmer","year":"2024","journal-title":"Blood"},{"issue":"13","key":"2026111311220909900_bib39","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2009-09-199182","article-title":"Structure and function of factor XI","volume":"115","author":"Emsley","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2026111311220909900_bib40","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1021\/jm301757v","article-title":"Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site","volume":"56","author":"Karuturi","year":"2013","journal-title":"J Med Chem"},{"issue":"38","key":"2026111311220909900_bib41","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1016\/j.tetlet.2007.07.100","article-title":"Rapid and efficient microwave-assisted synthesis of highly sulfated organic scaffolds","volume":"48","author":"Raghuraman","year":"2007","journal-title":"Tetrahedron Lett"},{"issue":"52","key":"2026111311220909900_bib42","doi-asserted-by":"crossref","first-page":"e202402268","DOI":"10.1002\/chem.202402268","article-title":"Synthesis and reactivity of masked organic sulfates","volume":"30","author":"Kumar Villuri","year":"2024","journal-title":"Chem A Eur J"},{"key":"2026111311220909900_bib43","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/978-1-0716-1398-6_59","article-title":"Murine models in the evaluation of heparan sulfate-based anticoagulants","volume":"2303","author":"Mohammed","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"2","key":"2026111311220909900_bib44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1213\/ANE.0b013e31823a088c","article-title":"Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited","volume":"114","author":"Wolberg","year":"2012","journal-title":"Anesth Analg"},{"issue":"44","key":"2026111311220909900_bib45","doi-asserted-by":"crossref","first-page":"45470","DOI":"10.1074\/jbc.M406727200","article-title":"Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI","volume":"279","author":"Baglia","year":"2004","journal-title":"J Biol Chem"},{"issue":"5","key":"2026111311220909900_bib46","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/jth.14418","article-title":"Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI","volume":"17","author":"Li","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2026111311220909900_bib47","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1021\/jacsau.2c00569","article-title":"Glycosaminoglycans: what remains to be deciphered?","volume":"3","author":"Perez","year":"2023","journal-title":"JACS Au"},{"issue":"6","key":"2026111311220909900_bib48","doi-asserted-by":"crossref","first-page":"C1271","DOI":"10.1152\/ajpcell.00095.2022","article-title":"The glycosaminoglycan interactome 2.0","volume":"322","author":"Vallet","year":"2022","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"2026111311220909900_bib49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40248-015-0021-4","article-title":"Venous thromboembolism and lung cancer: a review","volume":"10","author":"Vitale","year":"2015","journal-title":"Multidiscip Respir Med"},{"issue":"2","key":"2026111311220909900_bib50","doi-asserted-by":"crossref","first-page":"106076","DOI":"10.1016\/j.isci.2023.106076","article-title":"Myeloid-cell-specific role of Gasdermin D in promoting lung cancer progression in mice","volume":"26","author":"Traughber","year":"2023","journal-title":"iScience"},{"issue":"3","key":"2026111311220909900_bib51","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/iep.12182","article-title":"New approaches in tail-bleeding assay in mice: improving an important method for designing new anti-thrombotic agents","volume":"97","author":"Saito","year":"2016","journal-title":"Int J Exp Pathol"},{"issue":"3","key":"2026111311220909900_bib52","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4103\/aca.aca_117_23","article-title":"Protamine and H. Interactions: A narrative review","volume":"27","author":"Crivellari","year":"2024","journal-title":"Ann Card Anaesth"},{"issue":"1","key":"2026111311220909900_bib53","first-page":"34","article-title":"Practical guide for anticoagulant and antiplatelet reversal in clinical practice","volume":"11","author":"Aldhaeefi","year":"2023","journal-title":"Pharmacy (Basel)"},{"key":"2026111311220909900_bib54","doi-asserted-by":"crossref","first-page":"24043","DOI":"10.1038\/srep24043","article-title":"Allosteric partial inhibition of monomeric proteases. Sulfated coumarins induce regulation, not just inhibition, of thrombin","volume":"6","author":"Verespy","year":"2016","journal-title":"Sci Rep"},{"key":"2026111311220909900_bib55","doi-asserted-by":"crossref","first-page":"10760296221132556","DOI":"10.1177\/10760296221132556","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after major gynecological cancer surgery: the VALERIA trial: Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial)","volume":"28","author":"Longo de Oliveira","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026111311220909900_bib56","doi-asserted-by":"crossref","first-page":"109500","DOI":"10.1016\/j.thromres.2025.109500","article-title":"Prolonged duration of pharmacological thromboprophylaxis following oncologic surgery: a systematic review and meta-analysis of RCTs","volume":"255","author":"Wang","year":"2025","journal-title":"Thromb Res"},{"issue":"8","key":"2026111311220909900_bib57","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jth.13009","article-title":"Venous thrombosis and cancer: from mouse models to clinical trials","volume":"13","author":"Hisada","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2026111311220909900_bib58","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.jtha.2025.06.030","article-title":"Venous thromboembolism in patients with cancer and factor XI deficiency","volume":"23","author":"Chrysafi","year":"2025","journal-title":"J Thromb Haemost"},{"key":"2026111311220909900_bib59","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/S0049-3848(20)30407-2","article-title":"Cancer animal models in thrombosis research","volume":"191","author":"Palacios-Acedo","year":"2020","journal-title":"Thromb Res"},{"issue":"9","key":"2026111311220909900_bib60","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/jth.13766","article-title":"Factor XI-deficient mice exhibit increased bleeding after injury to the saphenous vein","volume":"15","author":"Ay","year":"2017","journal-title":"J Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7621\/2600120\/blooda_adv-2026-019983-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7621\/2600120\/blooda_adv-2026-019983-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:22:24Z","timestamp":1794586944000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/22\/7621\/571043\/A-synthetic-small-molecule-allosteric-inhibitor-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,24]]},"references-count":60,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019983","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,24]]},"published":{"date-parts":[[2026,11,24]]}}}